|
Innovation, experience and a return on investment are the essential
factors that I bring together in the business of science incorporating clinical pathology with chemical biology producing
the deliverables of the future.
Email: mbascience@hotmail.com | Business:
www.biotechpharmasolutions.com LinkedIn: http://www.linkedin.com/in/markbanderson
|
..... |
Executive R&D Summary
|
||||||||||
EXPERIENCE
Creating value comes through innovation,
teamwork, scientific expertise, and a business savvy. I bring more than 20 years of experience in the Pharmaceutical R&D
industry.
My unique expertise includes clinical pathology, pharmaceutical R&D, pharmacology, with a
team-oriented and results-oriented management style. I have worked in infectious disease, cancer, neurodegeneration (neurology),
inflammatory disease, and blood coagulation and wound healing. I have worked with industry leaders, physicians, and
key opinion leaders (KOL) in dermatology, urology, ophthalmology, oncology, sinusitis, otitis, ENT, onychomycosis, cardiovascular
disease, neurology, pulmonary injury and chronic non-healing wounds; including new mechanisms of action, drug resistance,
biofilm, and virulence factors. I have experience with new chemical entities (NCE) and new drugs, biologics including new
biologic entities (NBE), and medical devices with the goal of achieving a competitive advantage, safe & effective marketable
products and a return on the investment.
The 21st century pharmaceutical and medical device landscapes are rapidly
changing and my experience integrates innovation, understanding physician and patient needs, teamwork in a culturally diverse
environment, and knowledge of how to drive agents and devices to the market.
EDUCATION
University of Massachusetts, Lowell, MA. - Clinical Pathology certification completed 2010.
Harvard University, Cambridge, MA. - Officer/Postdoctoral Fellow in the Department of Chemical Biology &
Chemistry completed 1992.
Purdue University, West Lafayette, IN. - Doctorate (Ph.D.) Natural Products &
Synthesis completed 1989.
University of Minnesota, Minneapolis, MN. - Bachelor of Science (B.S.) Chemistry,
Biochemistry, Microbiology and an undergraduate Research Thesis completed 1984.
EMPLOYMENT
Biotech
Pharma Solutions: President and Chief Scientific Officer, 2009 to Present – Pharma R&D
Consulting in drugs, biologics, medical devices, management, pharmaceutical R&D, pharmacology, pathology, formulations,
toxicology, international projects, and translational medicine in the area of infectious disease, inflammatory disease,
wound healing, neurology, oncology.
NovaBay Pharmaceuticals, Inc.: Chief Scientific Officer,
October 2009 to January 2012 – Pharmaceutical CSO in infectious diseases including ophthalmology/ENT, dermatology, urology,
sinusitis, onychomycosis, and hospital chronic non-healing wounds or wound healing, biofilm, drug resistance, and virulence
factors. Collaboration contacts Alcon (US) and Galderma (US & Fr).
Biotech Pharma Solutions:
President and Chief Scientific Officer, 2009 – Pharma R&D Consulting in drugs, biologics, medical devices, management,
pharmaceutical R&D, pharmacology, pathology, formulations, toxicology, international projects, and translational medicine,
in the area of oncology, neurology, infectious disease, dermatology, wound healing.
g
Myriad Genetics
& Myriad Pharmaceuticals: Vice President; Chemistry, 2003 to 2009 – Oncology, alzheimer’s genetics,
neurology, HIV, blood coagulation, disease, pathology, preclinical formulations, blood-brain barrier penetration, preclinical
formulations, polymorphs, selection of IND candidates, clinical development team, epigenetic and novel targets.
Elitra Pharmaceuticals: Senior Director, 2002 to 2003 – Infectious diseases (bacterial and fungal),
US & International collaborations and management.
Pfizer La Jolla Labs – Agouron
Pharmaceuticals: Associate Director of Medicinal Chemistry, 1997 to 2002 – Neuroendocrine, oncology, infectious
disease, medicinal chemistry, chemical biology, project leadership, drug design, SBDD, combinatorial lead expansion, and management.
Ligand Pharmaceuticals - Glycomed, Inc., Senior Research Scientist 1992 to 1997 -
International project leadership, oncology, inflammatory diseases and cell-adhesion mediated pathology, pulmonary and cardiovascular
injury, asthma and preclinical formulations.
SELECTED CONTINUING EDUCATION COLLOQUIUMS
ARVO
Clinical Trials Education Series: “Designing and Managing Clinical Trials in Eye Research.” May 1, 2010, 8:30
am – 5pm, Fort Lauderdale, FL.
UCSD School of Medicine, Office of Continuing Medical Education
ACS/UCSD Colloquium: “Angiogenesis Inhibitors in the Treatment of Solid Tumors”; Lee Rosen, M.D. January 22, 2001.
UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “Nonmyeloablative
Stem Cell Transplantation Using Low-dose Total Body Irradiation, Cyclosporine and MMF”; Peter McSweeney, M.D. February
26, 2001.
UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “Current
Therapeutic Opinions in the Management of B-Cell Malignancies”; Michael Keating, M.B., B.S. November 6, 2000.
UCSD School of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “New Endocrine Approaches
for Breast Cancer: Prevention and Treatment”; C. Kent Osborne, M.D. October 23, 2000.
UCSD School
of Medicine, Office of Continuing Medical Education ACS/UCSD Colloquium: “New Approaches to Therapy of Acute Myelogenous
Leukemia”; Richard Stone, M.D. October 2, 2000.
UCSD School of Medicine, Office of Continuing
Medical Education ACS/UCSD Colloquium: “Biology and Therapy of Advanced Prostate Oncology”; Christopher Logothetis,
M.D. June 8, 1999.
CONFERENCES AND PROFESSIONAL MEMBERSHIP
Memberships: Association for Molecular
Pathology (AMP); American Society for Investigative Pathology (ASIP); American Society of Microbiology (ASM); American Chemical
Society (ACS).
Wound Care: Society for Advanced Wound Care (SAWC), Wound Healing Society (WHS).
Medical Devices: Multidisciplinary Alliance Against Device-Related Infections (infectious disease) (MADRI), Pre-Filled
Syringes (4th PFS London).
Ophthalmology: Association for Research in Vision and Ophthalmology (ARVO), American
Academy of Ophthalmology (AAO).
Dermatology, Urology & Other: Interscience Conference on Antimicrobial
Agents & Chemotherapy (ICAAC), and Infectious Diseases Society of America (IDSA).
OVERVIEW OF INTELLECTUAL PROPERTY
100+ US & international issued and pending patent applications covering cancer (e.g. glioblastoma, methods for treating cancer, blood-brain barrier crossing agents, etc.); infectious disease (e.g. HIV maturation inhibitors, novel anti HIV, agents, etc.); cancer agents (oncology)associated with signal transduction (e.g. caspase activators and inducers of apoptosis); neuroendocrine (e.g. non-peptide GnRH agents); neurodegeneration (e.g. Alzheimer’s disease, neurology); kinases (e.g. cell cycle); viral infections; vascular disrupting agents; inflammatory disease, infectious disease, neurology, oncology topics, autoimmune diseases; etc. The end result is a productive history of multiple agents in the clinic. See below.
OVERVIEW OF PUBLICATIONS
50+
publications and cited publications in infectious disease clinical studies (e.g. impetigo, viral conjunctivitis); oncology
(e.g. vascular disrupting agents, novel agents); neurodegeneration (Alzhiemer’s, neurology); inflammatory disease (e.g.
lung and cardiac injuries); elucidation novel mechanisms of action; infectiious disease, bacterial biofilms; drug resistance;
reviews (e.g. 2009- Current Bioactive Compounds, 2003- Annual Reports in Medicinal Chemistry, 1994- Burger's Medicinal Chemistry
Chapter 22), etc.
40+ presentations and posters at Cambridge Healthtech Institute (CHI), Anti-Infectives
Summit, Society of Toxicology and American Heart Association; and posters at e.g. ARVO, ICAAC, IDSA, and ACS. See below.
|
..... |
|
||||||||||
Industrial Experience
Mark Anderson, Mark Brian Anderson
Biotech Pharma Solutions, San Francisco and
Boston; 2009 to Present
Mark B. Anderson, Ph.D.,
President and Chief Scientific Officer
Expertise: Pharmaceutical
R&D, Clinical Pathology, and Management
Consulting
services: Drugs, biologics, medical devices, management, pharmaceutical R&D, pharmacology, formulations, US and international
project coordination, safety/TOX, posology, WHO/INN/USAN, manuscript and medical writing, CRO/CDMO coordination, and translational
medicine. Provide an opinion of in vitro and in vivo biological data, pharmacologic data (PK, PD, ADMET, safety, sensitization,
etc), physiochemical properties, formulations, etc. Familiar with CDER, CBER and CDRH. Generally there are two types of service
options, one is advisory and management for clients looking to improve performance (drugs, biologics, devices and management),
finding collaborators and negotiating with partners; and the second for investors looking for an independent opinion on a
company’s technology, science or portfolio.
Focus: Driving science to market and translational medicine.
Area of expertise; oncology, neurology, infectious disease, inflammatory disease, HIV, wound healing.
Goals: As a business-science-minded executive, I have skills and experience that are applicable across multiple therapeutic
areas and product specialties in R&D and translational medicine. The primary goal is to enable viable flexible work plans
with business acumens to accelerate product development and return on the investment (ROI).
Therapeutic areas:
Infectious disease including ophthalmology/ENT, dermatology, urology, sinusitis, onychomycosis, and hospital chronic non-healing
wounds or wound healing, veterinary, biofilm, drug resistance, and virulence factors.
Material types: Biologics
(e.g. microRNA, monoclonal antibodies, proteins, etc), drug candidates (e.g. heterocycles, amino acids, small molecules, small
proteins, natural products, complex oligosaccharides, sulfatoids, molecular mimetics, metal chelators, etc), and devices (e.g.
device evaluation, prototype design, predicate devices, etc).
Disclosure: Consultant to NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc. Emeryville, CA October
2009 to 2012
Mark Anderson, Ph.D., Chief Scientific Officer
NovaBay Pharmaceuticals, Inc.: A clinical-stage infectious disease biotechnology company developing NeutroPhase®
and its lead Aganocide® NVC-422. NeutroPhase has FDA cleared 510(k)s for use in the irrigation, cleansing and debridement
of chronic non-healing wounds. NVC-422 is a broad-spectrum, fast-acting, non-antibiotic antimicrobial agent with a new mechanism
of action (MOA) that does not develop drug resistance for the non-systemic topical treatment of bacterial, viral and fungal
infections. Preclinical pipeline and preclinical drug development.
Business Units: 1) Ophthalmology/ENT e.g.
human adenoviral conjunctivitis (HAdV) with NVC-422 in a proprietary solution eye drop dsipensor; 2) Dermatology e.g. impetigo
1.5% NVC-422 in a proprietary topical hydrogel; 3) Urology e.g. NVC-422 in a proprietary irrigation solution for urinary catheter
blockage and encrustation (UCBE); and 4) Hospital wounds using the FDA cleared 510(k)s for NeutroPhase®. Additional R&D
in bacterial biofilm, resistance factors, virulence factors, onychomycosis, acne, sinusitis, otitis, and medical device opportunities.
Collaborations: Galderma, AS; Alcon; University of Innsbruck; and other confidential agreements.
Recent clinical publications: Impetigo clinical report – Iovino et al, International Journal of Clinical and Experimental
Pathology. 2011; 4(6):587-595. Mechanism of Action of NVC-422 against Human Adenoviral (HAdV) – Yoon et al, Antiviral
Res. 2011; 92: 470–478. PMID: 22024427. Overview of UCBE, Impetigo and HAdV – Darouiche et al, Drugs of the Future
2011, 36(9): 651-656. Chronic non-healing wounds with NeutroPhase® - Crew et al, at the Wound Healing Society (WHS)/ Symposium
on Advanced Wound Care (SAWC) (poster GP-16), Dallas, TX.
Recent research publications: Multiple manuscripts
published and in press.
Duties: Pharmaceutical R&D, manage all science and research, Business Development
support for new opportunities including in/out licensing, preclinical pipeline development, intellectual property, publications
and presentations, CEO’s executive committee, and support of clinical trial needs with corporate partners.
Worked hand-in-glove with the CEO, CFO and CAO for corporate development; worked the CEO with the board of directors (BOD);
responsible for the scientific advisory board (SAB); CEO’s Executive Committee (EC), discussions and presentations to
key opinion leaders (KOL), presentations for investors; presentations and work plans for new business development initiatives.
Intellectual property: Writing and review of manuscripts, papers, posters, interviews, invention disclosures,
patent applications, patent actions, and support with outside council.
Contributions: Clinical pathology
disease elucidation, pharmacology, medical writing, support of medical device initiatives, WHO/USAN/INN generic naming of
new chemical entities (NCE), work with surgeons and KOLs in clinical settings for product use, SBIR grants, mechanism of action
of NCEs, support of the CFR, ICH, CDER, CDRH guidelines, provide senior technical and business-science-minded leadership by
formulating, advocating and mentoring a science and development vision that complements the business vision promoting NovaBay
as a vibrant and innovative biotech.
Departmental: Line and matrix management of drug discovery, microbiology,
biochemistry, tissue and cell biology, pharmaceutical development (preclinical and clinical formulations and CRO/CDMO teams),
and analytical services.
Area of Expertise; infectious disease, inflammatory disease, wound healing, opthamology, oncology
Biotech
Pharma Solutions (BPS), Boston, Park City, and San Francisco 2009
Mark B. Anderson, Ph.D.,
President and Chief Scientific Officer
Biotech Pharma Solutions: Created in response to a need in the pharmaceutical, biologics and
medical device industries for effective business acumens to bring new products to market. There are unmet medical needs that
require effective therapeutics or devices, innovative ways to solve the delivery problem, clinical observation to improve
physician and patient ease of use, and cost effectiveness resulting in a marketable product.
Expertise: Pharmaceutical
R&D, Clinical Pathology, and Management
Area of Expertise; infectious disease, inflammatory disease, wound healing, opthamology, oncology
Consulting services: Drugs, biologics, medical devices, management, pharmaceutical R&D, pharmacology, formulations,
US and international project coordination, safety/TOX, posology, WHO/INN/USAN, manuscript and medical writing, CRO/CDMO coordination,
and translational medicine. Provide an opinion of in vitro and in vivo biological data, pharmacologic data (PK, PD, ADMET,
safety, sensitization, etc), physiochemical properties, salt forms, formulations, etc. Familiar with CDER, CBER and CDRH.
Generally there are two types of service options, one is advisory and management for clients looking to improve performance
(drugs, biologics, devices and management), finding collaborators and negotiating with partners; and the second for investors
looking for an independent opinion on a company’s technology, science or portfolio.
Focus: Driving
science to market and translational medicine.
Goals: As a business-science-minded executive, I have skills
and experience that are applicable across multiple therapeutic areas and product specialties in R&D and translational
medicine. The primary goal is to enable viable flexible work plans with business acumens to accelerate product development
and return on investment (ROI).
Therapeutic areas: Infectious diseases including ophthalmology/ENT, dermatology,
urology, sinusitis, onychomycosis, and hospital chronic non-healing wounds, veterinary, biofilm, drug resistance, and virulence
factors.
Material types: Biologics (e.g. microRNA, antagomirs, monoclonal antibodies, proteins, etc), drug
candidates (e.g. heterocycles, amino acids, small molecules, small proteins, natural products, complex oligosaccharides, sulfatoids,
molecular mimetics, metal chelators, etc), and devices (e.g. device evaluation, prototype design, predicate devices, etc).
Contracts: Confidential http://www.biotechpharmasolutions.com consulting agreements completed and business obligations concluded September 2009 prior
to joining NovaBay Pharmaceuticals full time.
Myriad
Genetics & Myriad Pharmaceuticals, Salt Lake City, Utah December 2003 to March 2009
Mark
B. Anderson, Ph.D., Vice President of Research; Chemistry
Myriad Pharmaceuticals: An R&D company focused on developing unique, best-in-class
therapeutic candidates in the areas of cancer and HIV. Myriad Pharmaceuticals now called Myrexis was a wholly owned subsidiary
of Myriad Genetics until it was spun-off in July 2009. Myriad Genetics is a molecular diagnostic company based in Salt Lake
City, Utah employing proprietary technologies that help doctors and patients understand the genetic basis of human disease
onset and progression.
Therapeutic areas and research: Alzheimer’s disease, neurology, oncology, infectious
disease, blood coagulation pathways, HIV, and other undisclosed targets identified through human genetics and other target
identification strategies.
Responsibilities: Pharmaceutical R&D, line and senior management, hit to lead
and medicinal chemistry, formulations, pharmacology, to being ideas to IND candidates efficiently.
Clinical
Pipeline (2009): Member of the development and IND teams for AzixaTM (verubulin; MPC-6827) for Non-Small-Cell Lung Cancer
(Phase 2), Melanoma (Phase 2), and Glioblastoma (Phase 2). ViveconTM (MPC-9055) was designed as an HIV maturation inhibitor
(Phase 1). MPC-2130 was for metastatic & blood cancers (Phase 1). MPC-0920 was developed for thrombosis (peptide mimic;
direct thrombin inhibitor; Phase 1). MPC-3100 was designed as an HSP-90 inhibitor for cancer. Additional work was done to
explore Alzheimer’s disease with FlurizanTM (tarenflurbil) as well as a back up program created. Composition of matter,
clinical use patents, and IND's to fully enable the pipeline (vide infra patents) were completed.
Preclinical
Pipeline: Drug discovery pipeline, program management, pharmacology and pathology data in addition to innovative medicinal
chemistry was used to produce IND-Ready agents such as MPI-0443803 (drug resistant cancers and brain cancer; including prodrugs);
MPI-451936 HIV (HIV fusion inhibitor) and MPI-461359 HIV (Maturation); MPC-2130 (chemical MOA); backup for MPC-0920; follow
on agents for MPC-3100 (in clinical development); MPI-442690 (backup for Alzheimer's Disease); prodrugs for treating neurodegenerative
disease agents; novel compounds and novel drug combinations for neurodegenerative disease (neurology) programs including
prodrugs and formulations; blood-brain-barrier predictions; chemical proteomic programs and strategies; oncology, antiviral,
and kinase targets that are clinically-relevant and clinically-important; novel drug-drug combinations for treating diseases;
drug delivery formulations; and numerous invention disclosures for novel agents and therapeutic targets and enzymes (vide
infr a patents). Worked hand-in-glove with clinical development, marketing, intellectual
property, and research teams.
Collaboration & Licensing: Joint collaborative research committee with
Abbott Labs; member of Myriad's in-license acquisition teams for the in-licensing of potential research (idea to IND) and/or
drug agents suitable for clinical development (IND to NDA).
Duties: Leadership and management by business
acumens; multiple program portfolio management resulting in compounds in the clinic; multidisciplinary program management;
worked closely with pharmacology/ADME TOX and discovery biology; generated USAN/INN names and worked with the Brand Institute
for nonproprietary (generic) names; medicinal chemistry and chemical biology; exploitation of pharmacology and biologic results
for the SXR chemical drug design matrix; a fully integrated chemistry department (medicinal, analytical, structure-based drug
design, chemistry follow up/hit-to-lead, pre-IND scale up); chemical proteomics with coordination of chemistry & biology
teams; share management responsibilities for the site as a member of the senior management team; numerous patents, invention
disclosures and expert relationship with the intellectual property department; active discussions in personalized medicine;
translational research/medicine; 1-5 year budgets; hiring; annual reviews; familiar with FDA CDER and 21 & 37 codes
of the federal regulations (CFR). Provide leadership in working with the WHO/USAN/INN for the generation of new stems for
new chemical entities (NCE). Responsible for setting and managing the overall departmental and cross-departmental scientific,
technical direction, and IND track development of all invented, existing or anticipated products in the pipeline; clinical
development team member; and responsible for: the professional development of the scientific staff. The results were to put
five compounds into clinical development. The most advanced and patented compounds target brain cancer (oncology), metastatic
cancers (oncology) and HIV (vide infra patents). The department was medicinal chemistry (15 FTE); hit to lead (15); and
computational chemistry (1). The result is a fun, innovative, fast-paced, results-driven, strategic, and team-oriented drug
discovery engine with a clear focus on the programs and corporate objectives. The return on the R&D investment is multiple
drug agents in the clinic.
Elitra Pharmaceuticals,
Inc., San Diego, CA June 2002 to Nov. 2003
Mark B. Anderson Ph.D., Senior
Director of Drug Discovery Chemistry R&D
Elitra Pharmaceuticals:
Elitra identified more than 6,000 essential genes in eleven (11) bacterial and fungal pathogens, infectious disease. Using
this screening technology we discovered new molecular targets for known drugs and targets for new chemical entities (NCE)
with our collaborations and internal programs. The approach enabled true functional genomics on a genome-wide scale to identify
all of the essential genes of pathogenic organisms. Elitra became part of a 3-way merger called RS3 in which the IP was purchased
by Trius, San Diego. Trius and Mycota (Elitra Canada) were acquired by Merck Pharmaceuticals.
Therapeutic
areas: Infectious disease and anti-bioterrorism related to Gram-negative, Gram-positive and fungal pathogens.
Collaborations: Merck & Co. (US); LG Life Sciences (Korea); BioLeads (EU); Kaken (Japan); deCODE genetics (Reykjavik,
Iceland and US facility); and others.
Duties: US and international R&D projects to discover and develop
new chemical entities to fight drug resistant infections (nfectious disease). Project coordination and line management duties.
Direct analytical and pharmacology departments in addition to working with all collaborators on chemistry and medicinal chemistry
SAR and drug development. Senior staff duties and budgets. Manage the large portfolio of projects focused on discovering,
developing, and commercializing novel small molecule drugs for the treatment of drug resistant infectious diseases with high
unmet needs. Target selection with collaborators; drug discovery with collaborators including drug design and pharmacology;
drug design and SAR/SXR for SBIR grants such as the compound design for Yersinia pestis a Gram-negative rod-shaped bacterium
belonging to the family Enterobacteriaceae (black plague); and competitive landscape review of bacterial and fungal drugs.
Work with agents and actions of traditional and non-traditional antimicrobial agents.
Responsible for in-license
reviews; ADMET; pharmacology (PK/PD); posology; safety and efficacy proposals; INN/USAN; FDA CDER procedures and ATC Codes.
Drive corporate collaborations to develop a plan for candidate compound selection and IND strategies. Review in-license opportunities
for IND, CMC, evaluate clinical development feasibility to end of Phase II (EOP2), discuss NDA/Marketing strategies as needed.
Mentor direct reports in Microbiology and Cell-Based assays (6); Pharmacology (ADMET and Pharmacodynamic) team (4); Analytical
team (2); drug discovery chemistry with LG (8) and deCODE (8), and work with CRO's.
Results: Successful collaborations
with potential candidates for further evaluation. Broad selection of chemical structure types and sizes (specifics confidential).
Pfizer La Jolla, CA October 1997 to June
2002
Mark B. Anderson, Ph.D. Associate Director of Medicinal Chemistry
Pfizer: Merged with Warner-Lambert (Agouron
Pharmaceuticals) February 3, 2000 for $87 billion USD. Focus was on anticancer and antiviral therapeutics using medicinal
chemistry with structure-based drug design (SBDD) and target library/combinatorial tools to accelerate R&D optimization
drug discovery and IND candidate selection efforts. I participated in the merging and reorganization of departments and teams
within the new Pfizer organization.
Therapeutic areas: Neuroendocrine (GnRH project leader), cancer kinase
(oncology) SBDD including CHK-1 and undisclosed targets, and antiviral (infectious disease, inflammatory disease) as targets.
Duties: Foster a team-oriented approach in medicinal chemistry, SBDD and combinatorial chemistries. Support
multiple projects via matrix management. Direct line management of more than 20 PhD/MS chemists, and 4 students; budgets;
work with teams on multiple program development. Program management included 5 PhD/MS pharmacologists, 2 PhD/MS DMPK specialists,
and 6+ PhD/MS biologists. Adoption of the Pfizer candidate compound nomination (CAN) guidelines. Member of the oncology discovery
advisory group (ODAG) and virology development group. Apply appropriate technologies such as microwave accelerated synthesis
and targeted library lead explosion. Incorporate SAR, pharmacology (PK, PD, ADMET), biomarkers, safety, toxicology and scale-up
considerations into drug designs. Contribute to the Pfizer idea bank.
Award: Agouron Pharmaceuticals President's
Award in drug discovery research (January 1999).
Results: Non-peptide GnRH (GnRH is a 10-mer peptide) development
candidates, multiple back-up candidates, peptides, peptide mimics, heterocycles, novel molecular rearrangement, contributions
to other candidate seeking programs, patents, publications, and capital equipment purchases. Area of expertise; oncology,
neurology, infectious disease, inflammatory disease.
Ligand Pharmaceuticals & Glycomed, Inc. - April 1992 to September 1997
Mark B. Anderson,
Ph.D. Senior Research Scientist and Project Leader
Ligand Pharmaceuticals: A cutting-edge drug discovery biotech in La Jolla, California with a
keen interest in the drug reformulation segment in the pharmaceutical industry. Glycomed, Inc. developed innovative pharmaceutical
products based on complex carbohydrates. May 18, 1995 Glycomed Inc., formally in Alameda, CA, operates as a subsidiary of
Ligand Pharmaceuticals Inc. San Diego California.
Therapeutic areas: The company's products (carbohydrate,
glycomimetic, small molecules and peptides) and were designed for the treatment of inflammatory disease, oncology, asthma,
cardiac ischemia-reperfusion injury, pulmonary injury, granulomatous vasculitis, eye disease and aberrant cell adhesion mediated
disease mediated by the E-, L-, and P-Selectins.
Collaborations: Drug R&D collaboration program with
Sankyo Co. Ltd, Tokyo, Japan against several proprietary disease targets (oncology) and we established drug candidate selection
criteria for advanced preclinical agents into the clinical pipeline; The Canadian Alberta Research Council (ARC); Johns Hopkins
(inflammatory disease) Asthma and Allergy Center, Baltimore, MD.; The University of Michigan Medical School Department of
Pathology; The University of Michigan Medical School Department of Pharmacology; The MD Anderson Cancer Center in Houston
Texas (wound healing); and The University of Michigan at Kalamazoo (wound healing).
Duties: Glycomed and
Sankyo project leader to discover and develop novel carbohydrate-based and non-carbohydrate containing therapeutic agents
to treat inflammatory disease, cancer (oncology), and aberrant cell adhesion. Conduct coordination committee meetings in Tokyo
and USA. Discover and optimize R&D hit to lead and lead to potential IND opportunities of small molecules and carbohydrate
derived agents based on glycomimetics of Sialyl Lewisx and Sialyl Lewisa.
Results: Designed carbohydrate
and non-carbohydrate based cell adhesion inhibitors and patent estates incorporating disease pathology, pharmacology and medicinal
chemistry SAR. Pharmacophore-based drug design, solid-phase (resin) syntheses; discrete parallel methodologies (Advanced ChemTech
496-MOS); approaches using Chiron Mimotope (PIN) technologies; solid-phase medicinal chemistry directed combinatorial technology
(resins focusing on spatially-addressable systems), and peptidomimetics. CRO scale up of potential IND candidates. Utilized
in vitro screening, cell-based assays, and cell-based rolling assay, cancer cell adhesion assay, and in vivo adhesion model
teams to obtain data and discuss the scientific results. Additional work was performed by making novel sulfatoids and sulfates
as sialic acid mimics. Promoted from Scientist III to Senior Research Scientist (July 1994).
|
..... |
|
||||||||||
Education
Mark Anderson, Mark Brian Anderson
University of Massachusetts:
Clinical Pathology Certification in the Clinical Laboratory and Nutritional Sciences Department
2009 to 2010; Advisor and Program Director: Dr. Eugene Rogers
Clinical Pathology: Studies the causes, nature and effects
of clinically relevant diseases. Clinical pathology combines the theoretical and technical knowledge of human anatomy and
physiology, clinical chemistry, genetics, immunology, microbiology, hematology, histocompatibility, cellular pathology and
other fields as they pertain to the diagnosis, monitoring and prevention of disease. Human
Development and Pathophysiology
(Dr. Alease Bruce); Advanced Pathophysiology (Dr. Kay Doyle, MT, ASCP); Health Data Analysis/Statistics (Dr. Beverly Volicer);
and Infectious Diseases (Dr. Guixin He).
Synthesis and purifications of the synthetic bioisostere incorporated PTX from the palytoxin carboxylic acid (PTC) derived from the selective hydrolysis of the vinylogous urea portion of PTX. Specially trained in the handling of PTX and PTC from a former Japanese Prof. Kishi group member.
Synthesis and incorporation of novel vinylogous urea bioisosteres of Palytoxin (PTX) into Palytoxin carboxylic acid (PTC), and the construction of many Palytoxin model systems. Methods included Kishi's Nickel Chromium coupling for the synthesis of the C 1 to C 16 and C 1 to C 25 Palytoxin model systems, worked on new synthetic building blocks, and carbon-glycosides. Testing of the novel palytoxin analogs were done at the Harvard University Medical School.
Mentor: Professor Phil. L. Fuchs, Ph.D.
Background: The Cytochalasins can be used as “molecular tools” to better understand actin polymerization, cell motility, ruffling, cell division, contraction, cell stiffness, cytoskeletal movement and other biological processes.
Constructed advanced intermediates and novel building blocks. Developed a unique Diels-Alder reaction, a novel intramolecular chiral acyl transfer strategy, expanded vinyl sulfone technologies, new cyclopentenylation methodology, anhydrous cerium (III) chloride methodologies, allylsilanes, beta-ethyl silyl thiol reagents (BEST), silicon and tin reagents, nucleophilic and electrophilic mercaptanylations and more.
Teaching Assistant Experience with multiple professors
General Chemistry TA: These courses introduced concepts such as stoichiometry, prediction of reaction products, thermodynamics, nuclear chemistry, electrochemistry, chemical kinetics, Conservation of energy, Conservation of mass, Law of constant composition, Gas laws, Solubility, Acid-base chemistry, Chemical bonding, Chemical equilibria and the basics of physical chemistry.
General Chemistry Laboratory TA: These courses applied the concepts acquired in the lectures and applied them in a supervised laboratory setting.
Organic Chemistry (Chemistry for Medicine/Health Care Fields): These courses were focused on those entering the medical and healthcare fields. Topics introduced the study of organic structures, properties, composition, reactions and preparation (by synthesis or by other means) of chemical compounds that contain carbon, basic nomenclature and an introduction to compounds that may contain any number of other elements, including hydrogen, nitrogen, oxygen, the halogens as well as phosphorus, silicon and sulfur.
Organic Chemistry Laboratory TA (Chemistry for Medicine/Health Care Fields): These courses applied the concepts acquired in the lectures and applied them in a supervised laboratory setting.
Organic Chemistry (Chemistry for Chemistry Majors): These courses were focused on those majoring in chemistry. Topics include the study of organic structures, properties, composition, reactions and preparation (by synthesis or by other means) of chemical compounds that contain carbon, nomenclature, examples that contain any number of other elements, including hydrogen, nitrogen, oxygen, the halogens as well as phosphorus, silicon and sulfur. The study and application of organic chemistry for medicinal chemistry lie on a continuum, but individuals with interests in these areas have one thing in common; they seek to understand how chemical structure correlates with biological activity.
Mentors: Professor Edward Leete, Ph.D. (April 1928 - Feb 8, 1992) and Professor Marian Stankovich, Ph.D. (1948 - June 19, 2007)
John Musser, Ph.D. (COO at Pharmagenesis) jmusser@pharmagenesis.com
Universities:
Professor Yoshito Kishi, Ph.D. kishi@chemistry.harvard.edu at Harvard University http://www.harvard.edu/
Professor Phil. Fuchs, Ph.D. pfuchs@purdue.edu Department of Chemistry at Purdue University http://www.purdue.edu/
Professor J. William Costerton, Ph.D.; Director, Microbial Research, Department of Orthopaedics, Allegheny General Hospital, and Director, Biofilm
Research, Center for Genomic Sciences, Allegheny-Singer Research Institute; email: wcostert@wpahs.org.
Professor Mahmoud A. Ghannoum, PhD, EMBA; Department of Dermatology, Director; Center for Medical Mycology; Co-Director at the Skin Diseases Research Center, Case Western Reserve, Cleveland, OH; email: Mahmoud.Ghannoum@UHhospitals.org.
LinkedIn: http://www.linkedin.com/in/markbanderson; Cyber Recommendations
AWARDS
2011 Notable People in R&D - Article of one of nine people recognized in the February issue of "R&D Directions" under Notable People in R&D Directions, page 16 2011. http://www.pharmalive.com/magazines/randd/
2003 Strathmore's Who's Who - in Leadership and Achievement
2003 United Who's Who - of Executives and Professionals
1999 President’s Award - Agouron Pharmaceuticals "President's Award in Drug Discovery, January 1999
|
..................
|
BAJJI, Ashok C.; KIM, Se-Ho; TANGALLAPALLY, Rajendra; MARKOVITZ, Benjamin; TROVATO, Richard; ANDERSON, Mark B.; WETTSTEIN, Daniel; SHENDEROVICH, Mark. Therapeutic Compounds And Their Use In Treating Diseases And Disorders. The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders, such as cancer.
2008 - Patent Number: 2008097341 (application serial number US2007/074478)
Kraig M. Yager, In Chul Kim, David Gerrish, Mark B. Anderson. ANTIVIRAL COMPOUNDS AND USE THEREOF. / COMPOSÉS ANTIVIRAUX ET LEUR UTILISATION. The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection. L'invention concerne des composés, des compositions pharmaceutiques et des procédés qui s'utilisent pour traiter une infection virale.
2008 - CIP of PCT/US06/000056
Cai, Sui Xiong; Anderson, Mark B.; Willardsen, Adam; Sirisoma, Nilantha Sudath; Zhang, Hong; Suzuki, Kazuyuki. PREPARATION OF SUBSTITUTED QUINAZOLINAMINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS. U.S. Pat. Appl. Publ. (2008), 50pp., Cont.-in-part of Appl. No. PCT/US06/000056. CODEN: USXXCO US 2008004297 A1 20080103 CAN 148:121727 AN 2008:12280. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics).
2007 - WO 2007095383
Walton, Ruth J.; Slade, Rachel M.; Willardsen, J. Adam; Weiner, Warren S.; Anderson, Mark B.. PRODRUGS OF PH ALKANOIC ACIDS WITH ENHANCED DELIVERY TO THE BRAIN OR ACROSS THE BLOOD-BRAIN-BARRIER FOR TREATMENT OF DEMENTIA. PCT Int. Appl. (2007), 56pp. CODEN: PIXXD2 WO 2007095383 A2 20070823 CAN 147:285038 AN 2007:941178. PCT/US2007/004189. Abstract: The invention relates prodrugs of phenyl alkanoic acids. The prodrugs of the invention can enhance and/or improve delivery of the phenyl alkanoic acid moiety to a desired target tissue. (drug design, drug discovery, blood brain barrier, SAR, SXR, Alzheimer's, synthesis, bioavailable, drug delivery, pharmacokinetics).
2007 - WO 2007076161
Bajji, Ashok C.; Kim, Se-Ho; Trovato, Richard; Mchugh, Robert J.; Markovitz, Benjamin; Anderson, Mark B.. PREPARATION OF OXAZOLE DERIVATIVES AS ANTIVIRAL AGENTS. PCT Int. Appl. (2007), 116pp. CODEN: PIXXD2 WO 2007076161 A2 20070705 CAN 147:143467 AN 2007:729694. PCT/US2006/049558. Abstract: Methods and pharmaceutical compositions for treating and/or delaying the onset of viral infection are provided. The pharmaceutical compositions include compounds having an oxazole core. Additionally, the compositions can be used to treat cardiovascular disorders and cancer. (drug design, drug discovery, SAR, SXR, HIV, antiviral, synthesis).
2007 - WO 2007002411, CA 2609280
Arranz Plaza, Esther; Yager, Kraig M.; Gerrish, David Allen; Anderson, Mark B.; Kim, In Chul; Kumar, Dange Vijay. ANTIVIRAL COMPOUNDS. . International Application Number: PCT/US2006/024493. PCT Int. Appl. (2007), 91pp. CODEN: PIXXD2 WO 2007002411 A1 20070104 CAN 146:100898 AN 2007:14669. 04.01.2007 C07J 53/00 PCT/US2006/024493 MYRIAD GENETICS, INC. The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection. (drug design, drug discovery, SAR, SXR, HIV, antiviral, synthesis).
2007 - US 20070299258, WO 2007134298
Bajji, Ashok C.; Kim, Se-Ho; Markovitz, Benjamin; Trovato, Richard; Tangallapally, Rajendra; Anderson, Mark B.; Wettstein, Daniel; Shenderovich, Mark; Vanecko, John A. PREPARATION OF SUBSTITUTED PURINAMINES AS ANTITUMOR AGENTS. PCT Int. Appl. (2007), 477pp. CODEN: PIXXD2 WO 2007134298 A2 20071122 CAN 148:11252 AN 2007:1332992. PCT/US2007/068899. Abstract: Compounds of the formula (I) (II) (III) in which A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group. B is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group Rl is chosen from hydro, alkyl, aryl, heteroaryl, amino, halo, sulfur, and thioalkyl. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, purine, pharmacokinetics, ADME).
2007 - WO 2007038684, CA 2623558, PCT/US2006/037903
Weiner, Warren S.; Slade, Rachel M.; Klimova, Yevgeniya I.; Walton, Ruth J.; Anderson, Mark B.. PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS. PYRROLE DERIVATIVES AS AMYLOID BETA 42-LOWERING AGENTS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS, AND USE IN THERAPY. PCT Int. Appl. (2007), 84pp. CODEN: PIXXD2 WO 2007038684 A2 20070405 CAN 146:379817 AN 2007:384648. PCT/US2006/037903. Abstract: Novel pyrrole derivatives are disclosed as Aβ42-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the Aβ42 peptide. (drug design, drug discovery, blood brain barrier, SAR, SXR, Alzheimer's, synthesis, oral, bioavailable, pharmacokinetics, pharmacodynamics, ADME).
2006 - WO 2006135383
Bajji, Ashok; Morham, Scott; Anderson, Mark B.; McHugh, Robert J.; Trovato, Richard; Weiner, Warren S.; Kim, Se-Ho. INDAZOLES: PREPARATION OF INDAZOLES FOR TREATING VIRAL INFECTION AND OTHER DISEASES MEDIATED BY RHO KINASE. PCT Int. Appl. (2006), 221pp. CODEN: PIXXD2 WO 2006135383 A2 20061221 CAN 146:62713 AN 2006:1338316. PCT/US2005/027730. Abstract: Methods and pharmaceutical compositions for treating and/or delaying the onset of viral infection are provided. The pharmaceutical compositions include compounds having an indazole core. Additionally, the compositions can be used to treat cardiovascular disorders and cancer. (drug design, drug discovery, SAR, SXR, cancer, tumor, synthesis, pharmacokinetics, pharmacodynamics, ADME).
2006 - WO 2006074223, CA 2593005
Cai, Sui Xiong; Anderson, Mark B.; Willardsen, Adam; Jiang, Songchun; Halter, Robert J.; Slade, Rachel; Klimova, Yevgeniya. PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF. International Application Number: PCT/US2006/000176. PCT Int. Appl. (2006), 97 pp. CODEN: PIXXD2 WO 2006074223 A2 20060713 CAN 145:145755 AN 2006:676927. Disclosed are 1-arylamino-phthalazines, 4-arylamino-benzo[d][1,2,3]triazines, and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, pharmacokinetics, ADME).
2006 - US 20080051398, WO 2006074187, CA 2592971
Cai, Sui Xiong; Anderson, Mark B.; Willardsen, Adam; Sirisoma, Nilantha Sudath. METHOD OF TREATING BRAIN CANCER. International Application Number: PCT/US2006/000122. PCT Int. Appl. (2006), 90 pp. CODEN: PIXXD2 WO 2006074187 A2 20060713 CAN 145:145733 AN 2006:675266. 13.07.2006 A61K 39/395 PCT/US2006/000122 MYRIAD GENETICS, INC. Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to the use of these compounds in treating brain cancer. http://www.freepatentsonline.com/y2008/0051398.html (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, pharmacokinetics, pharmacodynamics, ADME).
2006 - WO 2006074147, CA 2592900
Cai, Sui Xiong; Anderson, Mark B.; Willardsen, Adam; Sirisoma, Nilantha Sudath; Zhang, Hong; Suzuki, Kazuyuki. NITROGEN CONTAINING BICYCLIC COMPOUNDS AND THERAPEUTICAL USE THEREOF. International Application Number: PCT/US2006/000056. 13.07.2006 C07D 401/00 MYRIAD GENETICS, INC. Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. (drug design, drug discovery, SAR, SXR, cancer, tumor, synthesis, pharmacokinetics).
2006 - WO 2006074147
Cai, Sui Xiong; Anderson, Mark B.; Willardsen, Adam; Sirisoma, Nilantha Sudath; Zhang, Hong; Suzuki, Kazuyuki. PREPARATION OF 4-ARYLAMINO-QUINAZOLINES AND THEIR ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS. PCT Int. Appl. (2006), 133 pp. CODEN: PIXXD2 WO 2006074147 A2 20060713 CAN 145:145736 AN 2006:678591. (drug design, drug discovery, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics).
2006 - WO 2006041874, CA 2582674, PCT/US2005/035747
Slade, Rachel; Klimova, Yevgeniya; Halter, Robert J.; Yungai, Ashantai J.; Weiner, Warren S.; Walton, Ruth J.; Willardsen, Jon Adam; Anderson, Mark B.; Zavitz, Kenton. COMPOUNDS FOR ALZHEIMER'S DISEASE. International Application Number: PCT/US2005/035747. PCT Int. Appl. (2006), 300 pp. CODEN: PIXXD2 WO 2006041874 A2 20060420 CAN 144:412361 AN 2006:361235. 20.04.2006 C07D 209/04 MYRIAD GENETICS, INC. (drug design, drug discovery, blood brain barrier, SAR, SXR, Alzheimer's, synthesis, pharmacokinetics, pharmacodynamics, ADME).
2006 - US 7101878, WO 20040010033 (2004), WO00/20358
Anderson, Mark Brian; Vazir, Haresh N.; Luthin, David Robert; Paderes, Genevieve Deguzman; Pathak, Ved P.; Christie, Lance Christopher; Hong, Yufeng; Tompkins, Eileen Valenzuela; Li, Haitao; Faust, James. NON-PEPTIDE GNRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION. PCT/US2007/068899. Also see Appl. No. 9/763,216. PCT Filed Aug. 20, 1999, PCT No. PCT/US99/18790 § 371(c)(1), (2), (4) Date Feb. 20, 2001, PCT Pub. No. WO00/20358, PCT Pub. Date Apr. 13, 2000. Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, bioavailable, pharmacokinetics, pharmacodynamics, ADME).
2006 - WO 2006074187
Cai, Sui Xiong; Anderson, Mark B.; Willardsen, Adam; Sirisoma, Nilantha Sudath. PREPARATION OF 4-ARYLAMINO-QUINAZOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS. PCT Int. Appl. (2006), 90 pp. CODEN: PIXXD2 WO 2006074187 A2 20060713 CAN 145:145733 AN 2006:675266. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics, pharmacodynamics, ADME).
2005 - WO 20050250846, USPTO Application: 20050250846
Mark B. Anderson, Lance Christopher Christie, Quyen-Quyen Thuy Do, Yufeng Hong, Haitao Li, Ranjan Jagath Rajapakse, Eric T. Sun, Eileen Valenzuela Tompkins, Jun Feng, Ved P. Pathak. USPTO Application #: 20050250846. NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE. Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics, pharmacodynamics, ADME).
2005 - US 6903132
Anderson, Mark B.; Christie, Lance Christopher; Do, Quyen-Quyen Thuy; Feng, Jun; Hong, Yufeng; Li, Haitao; Pathak, Ved P.; Rajapakse, Ranjan Jagath; Sun, Eric T.; Tompkins, Eileen Valenzuela. NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE. Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described. (drug design, drug discovery, blood brain barrier, SAR, SXR, prodrugs, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics, pharmacodynamics, ADME).
2004 - US 20040053951
Christie, Lance C.; Anderson, Mark B.; Feng, Jun; Hong, Yufeng; Pathak, Ved P.; Rajapakse, Ranjan J.; Tompkins, Eileen V.; Vazir, Haresh; Li, Haitao. NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE. Pfizer Inc. No. 10364193 filed on 02/11/2003. Abstract: Non-peptide GnRH agents that inhibit the effect of gonadotropin-releasing hormone are described. Such agents are useful for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. United States Application 20040053951 A1. (drug design, drug discovery, SAR, SXR, cancer, tumor, synthesis, pharmacokinetics, pharmacodynamics, ADME).
2004 - US 20040014787
Mark B. Anderson; Lance Christopher Christie, Ballwin; Quyen-Quyen Thuy Do; Jun Feng; Yufeng Hong, San; Haitao Li, San Diego; Ved P. Pathak, San Diego; Ranjan Jagath Rajapakse; Eric T. Sun, San; Eileen Valenzuela Tompkins. US 20040014787A1. 2004/0014787 Al. NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE. Agouron Pharmaceuticals, Inc. Appl. No.: 10/459,364. Filed: Jun. 11, 2003 Related U.S. Application Data. Provisional application No. 60/388,788, filed on Jun. 13, 2002. Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, pro- drugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone- dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described. (drug design, drug discovery, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics, pharmacodynamics, ADME).
2004 - US 6833372
Christie, Lance C.; Anderson, Mark B.; Feng, Jun; Hong, Yufeng; Pathak, Ved P.; Rajapakse, Ranjan J.; Tompkins, Eileen V.; Vazir, Haresh; Li, Haitao. NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE. Pfizer Inc. No. 10364193 filed on 02/11/2003 Non-peptide GnRH agents that inhibit the effect of gonadotropin-releasing hormone are described. Such agents are useful for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. (drug design, drug discovery, SAR, SXR, cancer, tumor, synthesis, pharmacokinetics, ADME).
2003 - WO 2003106446, CA 2489252
Anderson, Mark Brian; Christie, Lance Christopher; Do, Quyen-Quyen Thuy; Feng, Jun; Hong, Yufeng; Li, Haitao; Pathak, Ved Prakash; Rajapakse, Ranjan Jagath; Sun, Eric Tak On; Tompkins, Eileen Valenzuela. NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE. (PREPARATION OF FURANCARBONYLHYDRAZINES AS INHIBITORS OF GONADOTROPIN-RELEASING HORMONE.) 24.12.2003 A61K 31/341 PCT/IB2003/002379 PFIZER INC. PCT Int. Appl. (2003), 115 pp. CODEN: PIXXD2 WO 2003106446 A1 20031224 CAN 140:42021 AN 2003:1006973. Methods for synthesizing the compounds and intermediates useful in their preparation are also described. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, prodrugs, pharmacokinetics, pharmacodynamics, active metabolites, ADME).
2003 - WO 2003068769, CA 2418712
Christie, Lance; Anderson, Mark, Brian; Feng, Jun; Hong, Yufeng; Pathak, Ved, Prakash; Rajapakse, Ranjan, Jagath; Tompkins, Eileen, Valenzuela; Vazir, Haresh; Li, Haitao. NON-PEPTIDE COMPOUNDS AFFECTING THE ACTION OF GONADOTROPIN-RELEASING HORMONE (GNRH). International Application Number: 21.08.2003 C07D 405/12 PCT/IB2003/000316 PFIZER INC. Non-peptide GnRH agents that inhibit the effect of gonadotropin-releasing hormone are described. Such agents are useful for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. The compound have the following structure: (Formula I). Canadian Patent (CA) of US 6833372. (CA 2418712) Non-peptide gnrh agents, pharmaceutical compositions, and methods for their use|Agents et compositions pharmaceutiques non peptidiques anti-gnrh et methodes d'utilisation. (drug design, drug discovery, SAR, SXR, cancer, tumor, synthesis, pharmacokinetics, pharmacodynamics, ADME).
2003 - US 6670167, US 20030235899 (2003) EP 1096014 (2001)
Chen, Ping; Anderson, Mark; Deng, Ya-Li; Gaur, Smita; Kan, Chen Chen; Luo, Chun; Lundgren, Karen; Margosiak, Stephen; Nguyen, Binh; O'Connor, Patrick; Register, James; Russell, Anna Tempczyk; Sarup, Jay. CATALYTIC DOMAIN OF THE HUMAN EFFECTOR CELL CYCLE CHECKPOINT PROTEIN KINASE CHK1 MATERIALS AND METHODS FOR IDENTIFICATION OF INHIBITORS THEREOF The present invention relates to the identification, isolation and purification of the catalytic domain of the human effector checkpoint protein kinase (hChk1). A 1.7Å crystal structure of the hChk1 kinase domain in the active conformation is reported herein. The kinase domain of hChk1 and its associated crystal structure is described for use in the discovery, identification and characterization of inhibitors of hChk1. This structure provides a three-dimensional description of the binding site of the hChk1 for structure-based design of small molecule inhibitors thereof as therapeutic agents. Inhibitors of hChk1 find utility in the treatment of hyperproliferative disorders such as HIV and cancer. http://www.wikipatents.com/6670167.html (drug design, drug discovery, SAR, SXR, cancer, tumor, crystal structure, kinase).
2003 - US 6646137
Anderson, Mark Brian; Polinsky, Alexander; Hong, Yufeng; Gregor, Vlad Edward. NON-PEPTIDE GNRH AGENTS. Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are of the following general formula, where X1, X2, Y, and Z are defined variables: STR1 Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described. (drug design, drug discovery, SAR, SXR, prodrugs, cancer, tumor, synthesis, pharmacokinetics, pharmacodynamics, ADME).
2003 - EP 1334972
Anderson, Mark B.; Christie, Lance C.; Feng, Jun; Hong, Yufeng; Li, Haitao; Pathak, Ved P.; Rajapakse, Ranjan; Tompkins, Eileen; Vazir, Haresh N. PREPARATION OF NON-PEPTIDE COMPOUNDS AFFECTING THE ACTION OF GONADOTROPIN-RELEASING HORMONE (GNRH). International Application Number: Eur. Pat. Appl. (2003), 1 p. CODEN: EPXXDW EP 1334972 A1 20030813 CAN 139:179968 AN 2003:626431. (drug design, drug discovery, SAR, SXR, cancer, tumor, synthesis).
2002 - WO 2002098363, CA 2449843
Sun, Eric T.; Anderson, Mark B.; Anderes, Kenna L.; Christie, Lance C.; Do, Quyen-Quyen T.; Feng, Jun; Goetzen, Thomas; Hong, Yufeng; Iatsimirskaia, Eugenia A.; Li, Haitao; Luthin, David R.; Paderes, Genevieve D.; Pathak, Ved P.; Rajapakse, Ranjan Jagath; Shackelford, Scott; Tompkins, Eileen Valenzuela; Truesdale, Larry K.; Vazir, Haresh. NON-PEPTIDE FURANYL GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE, AND PROCESSES FOR PREPARING THEM AND THEIR INTERMEDIATES. PCT Int. Appl. (2002), 243 pp. CODEN: PIXXD2 WO 2002098363 A2 20021212 CAN 138:24635 AN 2002:946059. PCT/US2002/017846. Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described. (drug design, drug discovery, SAR, SXR, cancer, tumor, synthesis, pharmacokinetics, pharmacodynamics, ADME).
2001 - US 6218426 (2001), WO 1999/044987 (1999)
Anderson, Mark; Polinsky, Alexander; Hong, Yufeng; Gregor, Vlad. NON-PEPTIDE GnRH AGENTS 10.09.1999 C07C 279/12 PCT/US1999/004457. PCT Int. Appl. (1999), 90 pp. CODEN: PIXXD2 WO 9944987 A1 19990910 EP1068178, WO09944987. CA2322444 CAN 131:214183 AN 1999:576906 AGOURON PHARMACEUTICALS, INC. Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are of general formula (I), where X1, X2, Y, and Z are defined variables. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described. (SAR, SXR, synthesis).
2000 - US 7101878, WO 2000020358, EP1105120 (2000), WO 0020358 (2000)
Anderson, Mark Brian; Vazir, Haresh N.; Luthin, David Robert; Paderes, Genevieve Deguzman; Pathak, Ved P.; Christie, Lance Christopher; Hong, Yufeng; Tompkins, Eileen Valenzuela; Li, Haitao; Faust, James. NON-PEPTIDE GNRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION. PCT Int. Appl. (2000), 444 pp. CODEN: PIXXD2 WO 2000020358 A2 20000413 CAN 132:279106 AN 2000:241135. (drug design, drug discovery, synthesis, SAR, SXR).
1999 - WO 9929705
Anderson, Mark B.; Kobayashi, Yoshiyuki; Itoh, Kazuhiro; Holme, Kevin R.; Cui, Jingrong; Fugedi, Peter; Peto, Csaba F.; Wang, Li; Vazir, Harish. PREPARATION OF SIALYL LEWISX AND SIALYL LEWISA GLYCO-MIMETICS AS SELECTIN INHIBITORS. PCT Int. Appl. (1999), 184 pp. CODEN: PIXXD2 WO 9929705 A2 19990617 CAN 131:45047 AN 1999:390408. (drug design, drug discovery, synthesis, SAR, SXR).
1999 - WO 9944987
Anderson, Mark; Polinsky, Alexander; Hong, Yufeng; Gregor, Vlad. PREPARATION OF N-(HETERO)AROYL-N-(GUANIDINOMETHYLARYLMETHYL)-N-[(POLY)CYCLYLMETHYL)]AMINES AS NON-PEPTIDE GONADOTROPIN RELEASING HORMONE INHIBITORS. PCT Int. Appl. (1999), 90 pp. CODEN: PIXXD2 WO 9944987 A1 19990910 CAN 131:214183 AN 1999:576906. (drug design, drug discovery, synthesis, SAR, SXR).
1999 - WO 9929706
Anderson, Mark B.; Levy, Daniel E.; Holme, Kevin R. PREPARATION OF DISALICYLATE ANALOG BASED SIALYL LEWISX MIMETICS AS ANTIINFLAMMATORY AGENTS AND SELECTIN RECEPTORS. PCT Int. Appl. (1999), 104 pp. CODEN: PIXXD2 WO 9929706 A2 19990617 CAN 131:45048 AN 1999:390409. (drug design, drug discovery, synthesis, SAR, SXR).
1999 - US 6218426, EP1068178, WO09944987, CA2322444
US Patent 6,218,426 M. B. Anderson, A. Polinsky, Y. Hong, Vlad. E. Gregor. NON-PEPTIDE GNRH AGENTS. EP1068178, WO09944987. CA2322444. (drug design, drug discovery, synthesis, SAR, SXR).
1998 - US CIP of US 5837689
Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga. PREPARATION OF SIALYL LEWIS-X MIMETICS CONTAINING NAPHTHYL BACKBONES AS SELECTIN INHIBITORS. U.S. (1998), 48 pp., Cont.-in-part of U. S. Ser. No. 446,185. CODEN: USXXAM US 5837689 A 19981117 CAN 130:14166 AN 1998:752223. (drug design, drug discovery, synthesis, SAR, SXR).
1998 - US CIP of US 5789385
Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga; Cui, Jing Rong. PREPARATION OF SIALYL LEWIS X MIMETICS CONTAINING PHENYL BACKBONES AS SELECTIN INHIBITORS. U.S. (1998), 55 pp. Cont.-in-part of U.S. Ser. No. 446,185. US 5789385 A 19980804 CAN 129:161815 AN 1998:534879. (drug design, drug discovery, synthesis, SAR, SXR).
1998 - US 5837690
B. N. Narasinga Rao, M.B. Anderson, and J. H. Musser. DERIVATIVES OF TRITERPENOID ACIDS AND USES THEREOF. International Patents: AU6529194. Abstract: Derivatives of triterpenoid acids and uses thereof.: United States Patent 5837690 Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease. (drug design, drug discovery, synthesis, SAR, SXR).
1998 - US 5837689
M. B. Anderson, D. Levy, P. Tang, J. H. Musser, B. N. N. Rao, SIALYL LEWIS-X MIMETICS CONTAINING NAPHTHYL BACKBONES. International Patents: AU2137297, WO9731006. Abstract: Sialyl lewis-x mimetics containing naphthyl backbones: United States Patent 5837689 (drug design, drug discovery, synthesis, SAR, SXR).
1998 - US 5789385, WO 9730984 (1997)
M. B. Anderson, D. Levy, P. Tang, J. H. Musser, B. N. N. Rao, J. Cui, SIALYL LEWISX MIMETICS CONTAINING PHENYL BACKBONES. AU2136597, WO9730984. (drug design, drug discovery, synthesis, SAR, SXR). 1997 - WO 9730984 (drug design, drug discovery, synthesis, SAR, SXR).
1998 - US 5763582
B. N. Narasinga Rao, M.B. Anderson, and J. H. Musser. DERIVATIVES OF TRITERPENE ACIDS AND USES THEREOF. Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease. (drug design, drug discovery, synthesis, SAR, SXR).
1998 - U.S. (1998), 48 pp., Cont.-in-part of U. S. Ser. No. 446,185. US 5837689
Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga. PREPARATION OF SIALYL LEWISX MIMETICS CONTAINING NAPHTHYL BACKBONES AS SELECTIN INHIBITORS. U.S. (1998), 48 pp., Cont.-in-part of U. S. Ser. No. 446,185. US 5837689 A 19981117 CAN 130:14166 AN 1998:752223. (drug design, drug discovery, synthesis, SAR, SXR).
1998 - CIP of US 5837689
Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga. PREPARATION OF SIALYL LEWIS-X MIMETICS CONTAINING NAPHTHYL BACKBONES AS SELECTIN INHIBITORS. U.S. (1998), 48 pp., Cont.-in-part of U. S. Ser. No. 446,185. CODEN: USXXAM US 5837689 A 19981117 CAN 130:14166 AN 1998:752223. (drug design, drug discovery, synthesis, SAR, SXR).
1998 - CIP of US 5789385
Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga; Cui, Jing Rong. PREPARATION OF SIALYL LEWISX MIMETICS CONTAINING PHENYL BACKBONES AS SELECTIN INHIBITORS. U.S. (1998), 55 pp., Cont.-in-part of U.S. Ser. No. 446,185. CODEN: USXXAM US 5789385 A 19980804 CAN 129:161815 AN 1998:534879. (drug design, drug discovery, synthesis, SAR, SXR).
1997 - WO 9731007, AU1975297
Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga. PREPARATION OF SIALYL LEWISX MIMETICS CONTAINING FLAVANOID BACKBONES AS SELECTIN INHIBITORS. PCT Int. Appl. (1997), 160 pp. CODEN: PIXXD2 WO 9731007 A1 19970828 CAN 127:248358 AN 1997:579729. (drug design, drug discovery, synthesis, SAR, SXR).
1997 - WO 9731006
Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga. PREPARATION OF SIALYL LEWISX MIMETICS CONTAINING NAPHTHYL BACKBONES AS SELECTIN INHIBITORS. PCT Int. Appl. (1997), 178 pp. CODEN: PIXXD2 WO 9731006 A1 19970828 CAN 127:248357 AN 1997:579728. (drug design, drug discovery, synthesis, SAR, SXR).
1997 - WO 9731007
Anderson, Mark B.; Levy, Daniel E.; Tang, Peng Cho; Musser, John H.; Rao, Narasinga. PREPARATION OF SIALYL LEWISX MIMETICS CONTAINING FLAVANOID BACKBONES AS SELECTIN INHIBITORS. PCT Int. Appl. (1997), 160 pp. CODEN: PIXXD2 WO 9731007 A1 19970828 CAN 127:248358 AN 1997:579729. (drug design, drug discovery, synthesis, SAR, SXR).
1997 - US 5695738
M.B. Anderson and J. H. Musser, STEROIDAL C-GLYCOSIDES. Glycomed Incorporated U.S. (1997), 20 pp. US 5695738 A 19971209 CAN 128:75635 AN 1997:803505. Abstract: Compositions of sterodial glycosides are described wherein the glycoside is linked directly, or indirectly to a desired steroidal compound via a carbon, or similar stable linkage, and methods of using the compositions to treat patients by binding to and/or blocking cellular receptors for a variety of diseases including cancer, inflammation, and autoimmune diseases. (drug design, drug discovery, synthesis, SAR, SXR).
1997 - US 5688922
B.N. Narasinga Rao, M. B. Anderson, and J. H. Musser. Substituted Fucopyranosides. SUBSTITUTED FUCOPYRANOSIDES 2-Chloromethyl-3-(tri-O-benzyl-α-L-C-fucopyranoside)-1-propene and methods of making the same are described. Methods of combining this substituted fucopyranose with triterpenoid acid also are described. (drug design, drug discovery, synthesis, SAR, SXR).
1997 - US 5679644
B.N. Narasinga Rao, M. B. Anderson, and J. H. Musser. METHODS OF TREATING DISEASES USING TRITERPENOID ACID DERIVATIVES. (Triterpenoid acid derivatives, dual pharmacophobic activities, selectin ligand and leukotriene biosynthetic inhibitory activities, cancer, diseases associated with the inflammatory process, diagnosis of disease, drug design, drug discovery, synthesis, SAR, SXR, inflammation).
1997 - US 5643884
Anderson, Mark Brian; Musser, John Henry. LUPANE TRITERPENOID DERIVATIVES. PCT Int. Appl. (1995), 42 pp. CODEN: PIXXD2 WO 9504526 A1 19950216 CAN 122:256432 AN 1995:516374, AU7520594, CA2169291, EP0714291, WO9504526.US Patent Issued on July 1, 1997, United States Patent 5643884 (drug design, drug discovery, synthesis, SAR, SXR, HIV, antiviral, cancer, tumor).
1997 - US 5624909
B.N. Narasinga Rao, M. B. Anderson, J. J. Nalway, and J. H. Musser. DERIVATIVES OF TRITERPENE ACIDS AS INHIBITORS OF CELL ADHESION MOLECULES ELAM-1 (E-SELECTIN) AND LECAM-1 (L-SELECTIN). Abstract: Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (e-selectin) and LECAM-1 (l-selectin): United States Patent 5624909 (Triterpenoid acid derivatives, dual pharmacophobic activities, selectin ligand and leukotriene biosynthetic inhibitory activities, cancer, diseases associated with the inflammatory process, diagnosis of disease, drug design, drug discovery, synthesis, SAR, SXR, inflammation).
1996 - WO 9636627
Anderson, Mark Brian; Musser, John H. PROCESS FOR THE PREPARATION OF ACTIVATED GLYCOMIMETIC C-GLYCOSIDES AS SELECTIN INHIBITORS. PCT Int. Appl. (1996), 132 pp. CODEN: PIXXD2 WO 9636627 A1 19961121 CAN 126:89699 AN 1997:51546. (drug design, drug discovery, synthesis, SAR).
1996 - US 5527890, CA 2160370, EP 0693079, AU 6529194, WO 9424145
M.B. Anderson, B. N. Narasinga Rao, and J. H. Musser. DERIVATIVES OF TRITERPENE ACIDS AND USES THEREOF. International Patents: CA2160370, EP0693079, AU6529194, WO9424145. United States Patent 5527890 (Triterpenoid acid derivatives, dual pharmacophobic activities, selectin ligand and leukotriene biosynthetic inhibitory activities, cancer, diseases associated with the inflammatory process, diagnosis of disease, drug design, drug discovery, synthesis, SAR, SXR, inflammation).
1996 - US 5519008, AU 5160093, AU 675085, EP 0691813, AU 675085, WO 9405152
B.N. Narasinga Rao, M. B. Anderson, J. J. Nalway, and J. H. Musser. DERIVATIVES OF TRITERPENE ACIDS AS INHIBITORS OF CELL ADHESION MOLECULES ELAM-1 (E-SELECTIN) AND LECAM-1 (L-SELECTIN). International Patents: AU5160093, AU675085, EP0691813, AU675085, WO9405152. United States Patent 5519008 Abstract: Triterpenoid acid derivatives have been found to have structures similar to natural ligands to the extent that these derivatives bind to natural selectin receptors including endothelial leukocyte adhesion molecule-1 (ELAM-1) and leukocyte/endothelial cell adhesion molecule-1 (LECAM-1). The molecules can be administered to the patients by themselves or in pharmaceutical formulations; in order to alleviate inflammation and/or treat other abnormalities associated with the excessive binding of leukocytes to endothelial receptors. (drug design, drug discovery, synthesis, SAR, SXR).
1996 - CA 2221589, AU 5855296, EP 0828729, WO 9636627
CA2221589, AU5855296, EP0828729, WO9636627: COLLECTION OF ACTIVATED GLYCOSIDE COMPOUNDS AND THEIR BIOLOGICAL USE. Anderson, Mark Brian and Musser, John H. US patent pending. (drug design, drug discovery).
1995 - WO 9504526
Anderson, Mark Brian; Musser, John Henry. LUPANE TRITERPENOID DERIVATIVES. PCT Int. Appl. (1995), 42 pp. CODEN: PIXXD2 WO 9504526 A1 19950216 CAN 122:256432 AN 1995:516374. (drug design, drug discovery, synthesis, SAR).
1994 - WO 9424145
Rao, Narasinga; Anderson, Mark Brian; Musser, John Henry. PREPARATION OF GLYCYRRHETINIC ACID DERIVATIVES AS SELECTIN LIGANDS AND LEUKOTRIENE BIOSYNTHESIS INHIBITORS. PCT Int. Appl. (1994), 49 pp. CODEN: PIXXD2 WO 9424145 A1 19941027 CAN 122:240077 AN 1995:468527. (drug design, drug discovery, synthesis, SAR, SXR).
1994 - WO 9405152
Rao, Narasinga; Anderson, Mark Brian; Naleway, John J.; Musser, John Henry. DERIVATIVES OF TRITERPENOID ACIDS AS INHIBITORS OF CELL-ADHESION MOLECULES ELAM-1 (E-SELECTIN) AND LECAM-1 (L-SELECTIN). PCT Int. Appl. (1994), 77 pp. WO 9405152 A1 19940317 CAN 120:315817 AN 1994:315817. (drug design, drug discovery, synthesis, SAR, SXR).
|
..... |
2011 - 3rd Anti Infectives Summit Q & A Online Interview. January 24 - 26, 2011, The Westin Philadelphia, PA.
2011 WHS/SAWC-NeutroPhase® with Sorbact® Dramatically Enhances the Speed of Wound Healing. John R. Crew, MD, Randell Varilla, RN, MSN, Allan Rocas III, RN, BSN, CWCN, Lu Wang, PhD, Dmitri Debabov, PhD, Ron Najafi, PhD, Mark Anderson PhD. Wound Care Center, Seton Medical Center, 1900 Sullivan Avenue, Daly City, CA 94015; and NovaBay Pharmaceuticals, Inc. 5980 Horton Street, Suite 550, Emeryville, CA 94608.
2011 ARVO- Aganocide®Compounds Effective Against Ophthalmic Pathogens. K.Najafi, A. Jekle, D. Debabov, S. Wilmarth, R. Jain, C. Celeri, M. Zuck, T. Shiau, C. Francavilla, E. Low and M. Anderson. Ophthalmology, Eye Institute of Marin, San Rafael, CA; and NovaBay Pharmaceuticals, Inc., Emeryville, CA 94608.
The findings could spur scientists to develop better antibiotics. If indole allows pathogenic bacteria to withstand antibiotics, it may be possible to thwart drug resistance by blocking indole signaling with small molecules, Collins says. Alternatively, "the findings suggest the possibility that scientists could one day use indole or an indole-based therapeutic, if proven safe, to help beneficial bacteria outcompete pathogenic bacteria in the urinary tract or intestinal system," says Mark Anderson, chief scientific officer of Emeryville, Calif.-based NovaBay Pharmaceuticals, which develops drugs for antibiotic-resistant infections.
Christopher M. Pleiman, Adam Willardsen, In Chul Kim, Warren S. Weiner, Chad Bradford, Bruce Roth, Harry Austin, Robert J. Halter, Chris Jolley, Gary Mather, Kenton Zavitz, Mark Anderson, Joshua Jones and Robert O. Carlson. Characterization of an orally bioavailable homolog of MPC-6827 (MPI-443803) that maintains high brain penetration. AACR 100th Meeting April 18-22, 2009. Denver, CO. Poster #5569. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics, pharmacodynamics, ADME).
2009 - Current Bioactive Compounds (Review)
Paul R. Sebahar, J. Adam Willardsen and Mark B. Anderson. Anticancer Agents: VTA or VDA. Current Bioactive Compounds, 2009, 5(1), 79-97. (vascular disrupting agents, vascular targeting agents, tumor, cancer, drug design, drug discovery, review).
2009 - AACR Poster #2706
AACR Poster March 30, 2009. Nilantha Sirisoma, Azra Pervin, Hong Zhang, Songchun Jiang, J. Adam Willardsen, Mark B. Anderson, Gary Mather, Christopher M. Pleiman, Shailaja Kasibhatla, Ben Tseng, John Drewe, Sui Xiong Cai. Discovery of N-(4-Methoxyphenyl)-N,2-dimethylquinazolin-4-amine, MPC-6827, a Potent Apoptosis Inducer and Efficacious Anticancer Agent with High Blood Brain Barrier Penetration. AACR 2009 Abstract #2706. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics, pharmacodynamics, ADME).
2009 - Journal of Medicinal Chemistry
Nilantha Sirisoma, Azra Pervin, Hong Zhang, Songchun Jiang, J. Adam Willardsen, Mark B. Anderson, Gary Mather, Christopher M. Pleiman, Shailaja Kasibhatla, Ben Tseng, John Drewe, Sui Xiong Cai. DISCOVERY OF N-(4-METHOXYPHENYL)-N,2-DIMETHYLQUINAZOLIN-4-AMINE, A POTENT APOPTOSIS INDUCER AND EFFICACIOUS ANTICANCER AGENT WITH HIGH BLOOD BRAIN BARRIER PENETRATION. J. Med. Chem., 2009, 52 (8), 2341-2351
- DOI: 10.1021/jm801315b web publication date 18 March 2009. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics, pharmacodynamics, ADME).
2008 - Bioorganic & Medicinal Chemistry Letters
David Gerrish, In Chul Kim, Dange V. Kumar, Harry Austin, Jennifer E. Garrus, Vijay Baichwal, Michael Saunders, Rena S. McKinnon, Mark B. Anderson, Robert Carlson, Esther Arranz-Plaza, Kraig M. Yager. TRITERPENE BASED COMPOUNDS WITH POTENT ANTI-MATURATION ACTIVITY AGAINST HIV-1. Bioorganic & Medicinal Chemistry Letters 18 (2008) 6377-6380. (drug design, drug discovery, SAR, SXR, HIV, antiviral, synthesis, pharmacokinetics, pharmacodynamic considerations, ADME).
2008 - Journal of Medicinal Chemistry
Nilantha Sirisoma, Shailaja Kasibhatla, Azra Pervin, Hong Zhang, Songchun Jiang, J. Adam Willardsen, Mark Anderson, Christopher M. Pleiman, Ben Tseng, John Drewe, Sui Xiong Cai. DISCOVERY OF 2-CHLORO-N-(4-METHOXYPHENYL)-N-METHYLQUINAZOLIN-4-AMINE (EP128265, MPI-0441138) AS AN INDUCER OF APOPTOSIS WITH IN VIVO ACTIVITY. J. Med. Chem. 2008, 51, 4771-4779. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics, pharmacodynamics, ADME).
2008 - ACS Poster MEDI-101
Cai, Sui Xiong; Sirisoma, Nilantha; Pervin, Azra; Zhang, Hong; Jiang, Songchun; Baichwal, Vijay; Willardsen, J. Adam; Anderson, Mark; Pleiman, Christopher M.; Tseng, Ben; Kasibhatla, Shailaja; Drewe, John. DISCOVERY OF 2-CHLORO-N-(4-METHOXYPHENYL)-N-METHYLQUINAZOLIN-4-AMINE (EP128265, MPI-0441138) AS A POTENT APOPTOSIS INDUCER USING ANTICANCER SCREENING APOPTOSIS PROGRAM (ASAP), A CELL- AND CASPASE-BASED PLATFORM. Abstracts of Papers, 235th ACS National Meeting, New Orleans, LA, United States, April 6-10, 2008 (2008), MEDI-101. CODEN: 69KNN3 AN 2008:389655. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable). (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics).
2008 - AACR Poster #1265
Nilantha Sirisoma, Azra Pervin, Hong Zhang, Songchun Jiang, Vijay Baichwal, J. Adam Willardsen, Mark Anderson, Christopher M. Pleiman, Ben Tseng, Shailaja Kasibhatla, John Drewe, Sui Xiong Cai. 2-CHLORO-N-(4-METHOXYPHENYL)-N-METHYLQUINAZOLIN-4-AMINE (EP128265, MPI-0441138) AS AN INDUCER OF APOPTOSIS WITH IN VIVO ACTIVITY. AACR April 12-16, 2008, San Diego, California, 99th Meeting Abstract # 1265. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable,pharmacokinetics, pharmacodynamics, ADME).
2007 - Purdue University Invited Lecture on Neurodegenerative and Alzheimer's disease
Anderson, Mark B. Invited Lecture for the Purdue University Special Topics Presentation: ALZHEIMER'S DISEASE - TARGETING AMYLOID. October 5th, 2007, West Lafayette, Indiana. (Alzheimer's, SXR, SAR, drug design, drug discovery, competitive analysis, review).
2006 - Journal of Medicinal Chemistry
Li, Haitao; Anderes, Kenna L.; Kraynov, Eugenia A.; Luthin, David R.; Do, Quyen-Quyen; Hong, Yufeng; Tompkins, Eileen; Sun, Eric T.; Rajapakse, Ranjan; Pathak, Ved P.; Christie, Lance C.; Vazir, Haresh; Castillo, Rosemary; Gregory, Margaret L.; Castro, Mary; Nared-Hood, Karen; Paderes, Genevieve; Anderson, Mark B.. DISCOVERY OF A NOVEL, ORALLY ACTIVE, SMALL MOLECULE GONADOTROPIN-RELEASING HORMONE (GNRH) RECEPTOR ANTAGONIST. [ERRATUM TO DOCUMENT CITED IN CA145:020415]. Journal of Medicinal Chemistry (2006), 49(19), 5849. CODEN: JMCMAR ISSN:0022-2623. CAN 145:347819 AN 2006:844175. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics, pharmacodynamics, ADME).
2006 - Journal of Medicinal Chemistry
Li, Haitao; Anderes, Kenna L.; Kraynov, Eugenia A.; Luthin, David R.; Do, Quyen-Quyen; Hong, Yufeng; Tompkins, Eileen; Sun, Eric T.; Rajapakse, Ranjan; Pathak, Ved P.; Christie, Lance C.; Vazir, Haresh; Castillo, Rosemary; Gregory, Margaret L.; Castro, Mary; Nared-Hood, Karen; Paderes, Genevieve; Anderson, Mark B.. DISCOVERY OF A NOVEL, ORALLY ACTIVE, SMALL MOLECULE GONADOTROPIN-RELEASING HORMONE (GNRH) RECEPTOR ANTAGONIST. Journal of Medicinal Chemistry (2006), 49(11), 3362-3367. CODEN: JMCMAR ISSN:0022-2623. CAN 145:20415 AN 2006:376441. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics, pharmacodynamics, ADME).
2003 - Journal of Pharmacology and Experimental Therapeutics
Anderes, Kenna L.; Luthin, David R.; Castillo, Rosemary; Kraynov, Eugenia A.; Castro, Mary; Nared-Hood, Karen; Gregory, Margaret L.; Pathak, Ved P.; Christie, Lance C.; Paderes, Genevieve; Vazir, Haresh; Ye, Qiang; Anderson, Mark B.; May, John M. BIOLOGICAL CHARACTERIZATION OF A NOVEL, ORALLY ACTIVE SMALL MOLECULE GONADOTROPIN-RELEASING HORMONE (GNRH) ANTAGONIST USING CASTRATED AND INTACT RATS. Journal of Pharmacology and Experimental Therapeutics (2003), 305(2), 688-695. CODEN: JPETAB ISSN:0022-3565. CAN 139:270462 AN 2003:329596. (drug design, drug discovery, blood brain barrier, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics, pharmacodynamics, ADME, chemical biology).
2003 - Journal of Organic Chemistry
Shackelford, Scott A.; Anderson, Mark B.; Christie, Lance C.; Goetzen, Thomas; Guzman, Mark C.; Hananel, Martha A.; Kornreich, Wayne D.; Li, Haitao; Pathak, Ved P.; Rabinovich, Alex K.; Rajapakse, Ranjan J.; Truesdale, Larry K.; Tsank, Stella M.; Vazir, Haresh N. ELECTROPHILIC TETRAALKYLAMMONIUM NITRATE NITRATION. II. IMPROVED ANHYDROUS AROMATIC AND HETEROAROMATIC MONONITRATION WITH TETRAMETHYLAMMONIUM NITRATE AND TRIFLIC ANHYDRIDE, INCLUDING SELECTED MICROWAVE EXAMPLES. Journal of Organic Chemistry (2003), 68(2), 267-275. CODEN: JOCEAH ISSN:0022-3263. CAN 138:169603 AN 2002:943438. Note erratum to CA138:169603 Journal of Organic Chemistry (2003), 68(7), 2986. CODEN: JOCEAH ISSN:0022-3263. CAN 140:41589 AN 2003:135779. (drug design, drug discovery, SAR, SXR, synthesis, nitration).
2003 - Annual Reports in Medicinal Chemistry (Review)
Anderson, Mark B.; Roemer, Terry; Fabrey, Robyn. PROGRESS IN ANTIFUNGAL DRUG DISCOVERY. Annual Reports in Medicinal Chemistry (2003), 38 163-172. CODEN: ARMCBI ISSN:0065-7743. CAN 140:228118 AN 2003:836070. (antiinfective, infective, fungal, review).
2002 - Pharmaceutical Research
Iatsimirskaia, Eugenia A.; Gregory, Margaret L.; Anderes, Kenna L.; Castillo, Rosemary; Milgram, K. Eric; Luthin, David R.; Pathak, Ved P.; Christie, Lance C.; Vazir, Haresh; Anderson, Mark B.; May, John M. EFFECT OF TESTOSTERONE SUPPRESSION ON THE PHARMACOKINETICS OF A POTENT GNRH RECEPTOR ANTAGONIST. Pharmaceutical Research (2002), 19(2), 202-208. CODEN: PHREEB ISSN:0724-8741. CAN 137:73535 AN 2002:200606. (drug design, drug discovery, SAR, SXR, cancer, tumor, synthesis, oral, bioavailable, pharmacokinetics, pharmacodynamics, ADME).
2002 - Bioorganic & Medicinal Chemistry Letters
Luthin, David R.; Hong, Yufeng; Tompkins, Eileen; Anderes, Kenna L.; Paderes, Genevieve; Kraynov, Eugenia A.; Castro, Mary A.; Nared-Hood, Karen D.; Castillo, Rosemary; Gregory, Margaret; Vazir, Haresh; May, John M.; Anderson, Mark B. CHARACTERIZATION OF MONO- AND DIAMINOPYRIMIDINE DERIVATIVES AS NOVEL, NONPEPTIDE GONADOTROPIN RELEASING HORMONE (GNRH) RECEPTOR ANTAGONISTS. Bioorganic & Medicinal Chemistry Letters (2002), 12(24), 3635-3639. CODEN: BMCLE8 ISSN:0960-894X. CAN 139:17096 AN 2002:878755. (drug design, drug discovery, SAR, SXR, cancer, tumor, synthesis, bioavailable, pharmacokinetics, pharmacodynamics, ADME, chemical biology).
2002 - Bioorganic & Medicinal Chemistry Letters
Luthin, David R.; Hong, Yufeng; Pathak, Ved P.; Paderes, Genevieve; Nared-Hood, Karen D.; Castro, Mary A.; Vazir, Haresh; Li, Haitao; Tompkins, Eileen; Christie, Lance; May, John M.; Anderson, Mark B. THE DISCOVERY OF NOVEL SMALL MOLECULE NON-PEPTIDE GONADOTROPIN RELEASING HORMONE (GNRH) RECEPTOR ANTAGONISTS. Bioorganic & Medicinal Chemistry Letters (2002), 12(23), 3467-3470. CODEN: BMCLE8 ISSN:0960-894X. CAN 138:378559 AN 2002:846220. (drug design, drug discovery, SAR, SXR, cancer, tumor, synthesis, pharmacokinetics, pharmacodynamics, ADME).
2001 - Combinatorial Chemistry Symposium
M. B. Anderson, V. Pathak, Y. Hong, L. Christie, R. Rajapakse, Q. Do, H. Li, E. Tompkins, J. Feng, D. Luthin, K. Nareed-Hood, M. Castro, S. Barnum , J. May, E. Iatsimirskaia, M. Gregory, Kenna Anderes, R. Castillo, G. Paderes. THE POWER OF MEDICINAL & COMBINATORIAL CHEMISTRIES IN DRUG DISCOVERY--AN ILLUSTRATION. UCSD San Diego Combinatorial Chemistry Symposium, CA 13 July 2001. (drug design, drug discovery, SAR, SXR, combinatorial, synthesis)
2001 - Australia Peptide Symposium Poster
Haitao Li, Quyen-Quyen Do, Yufeng Hong, Eileen Tompkins, Ved Pathak, Lance Christie, David Luthin, Genevieve Paderes, Haresh Vazir, and Mark B Anderson. DISCOVERY AND OPTIMIZATION OF POTENT SMALL MOLECULE GNRH (GONADOTROPIN RELEASING HORMONE) ANTAGONISTS 4th Australia Peptide Symposium Poster Oct 7-12 2001. (drug design, drug discovery, synthesis, SAR, SXR).
2000 - Society of Toxicology
M. B. Anderson, V. Pathak, Y. Hong, L. Christie, R. Rajapakse, Q. Do, H. Li, E. Tompkins, J. Feng, D. Luthin, K. Nareed-Hood, M. Castro, S. Barnum , J. May, E. Iatsimirskaia, M. Gregory, Kenna Anderes, R. Castillo, G. Paderes. THE POWER OF PARALLEL MEDICINAL CHEMISTRY IN DRUG DISCOVERY--AN ILLUSTRATION. Society of Toxicology, Irvine, CA 6 June 2000. (drug design, drug discovery, synthesis, SAR, SXR, review).
1998 - Journal of Pharmacology and Experimental Therapeutics
Kilgore, Kenneth S.; Powers, Karen L.; Imlay, Michelle M.; Malani, Anu; Allen, Douglas I.; Beyer, Jennifer T.; Anderson, Mark B.; Warren, Jeffrey S. THE CARBOHYDRATE SIALYL LEWISX (SLEX) SULFATED GLYCOMIMETIC GM2941 ATTENUATES GLUCAN-INDUCED PULMONARY GRANULOMATOUS VASCULITIS IN THE RAT. Journal of Pharmacology and Experimental Therapeutics (1998), 286(1), 439-446. CODEN: JPETAB ISSN:0022-3565. CAN 129:184095 AN 1998:454322. http://jpet.aspetjournals.org/cgi/content/full/284/1/427 (drug design, drug discovery, synthesis, SAR, SXR, pulmonary, lung, disease).
1998 - Journal of Pharmacology and Experimental Therapeutics
Kilgore, Kenneth S.; Tanhehco, Elaine J.; Park, James L.; Naylor, Keith B.; Anderson, Mark B.; Lucchesi, Benedict R. REDUCTION OF MYOCARDIAL INFARCT SIZE IN VIVO BY CARBOHYDRATE-BASED GLYCOMIMETICS. Journal of Pharmacology and Experimental Therapeutics (1998), 284(1), 427-435. CODEN: JPETAB ISSN:0022-3565. CAN 128:212667 AN 1998:53500. http://jpet.aspetjournals.org/cgi/content/full/284/1/427 (drug design, drug discovery, synthesis, SAR, SXR, cardiovascular).
1998 - American Journal of Respiratory Cell and Molecular Biology
Kim, Mi-Kyeong; Brandley, Brian K.; Anderson, Mark B.; Bochner, Bruce S. ANTAGONISM OF SELECTIN-DEPENDENT ADHESION OF HUMAN EOSINOPHILS AND NEUTROPHILS BY GLYCOMIMETICS AND OLIGOSACCHARIDE COMPOUNDS. American Journal of Respiratory Cell and Molecular Biology (1998), 19(5), 836-841. CODEN: AJRBEL ISSN:1044-1549. CAN 130:123771 AN 1998:758109. (drug design, drug discovery, synthesis, SAR, SXR, pulmonary).
1998 - Journal of Pharmacology and Experimental Therapeutics
Kilgore, Kenneth S.; Powers, Karen L.; Imlay, Michelle M.; Malani, Anu; Allen, Douglas I.; Beyer, Jennifer T.; Anderson, Mark B.; Warren, Jeffrey S. THE CARBOHYDRATE SIALYL LEWISX (SLEX) SULFATED GLYCOMIMETIC GM2941 ATTENUATES GLUCAN-INDUCED PULMONARY GRANULOMATOUS VASCULITIS IN THE RAT. Journal of Pharmacology and Experimental Therapeutics (1998), 286(1), 439-446. CODEN: JPETAB ISSN:0022-3565. CAN 129:184095 AN 1998:454322. (drug design, drug discovery, synthesis, SAR, SXR).
1998 - Journal of Pharmacology and Experimental Therapeutics
Kilgore, Kenneth S.; Tanhehco, Elaine J.; Park, James L.; Naylor, Keith B.; Anderson, Mark B.; Lucchesi, Benedict R. REDUCTION OF MYOCARDIAL INFARCT SIZE IN VIVO BY CARBOHYDRATE-BASED GLYCOMIMETICS. Journal of Pharmacology and Experimental Therapeutics (1998), 284(1), 427-435. CODEN: JPETAB ISSN:0022-3565. CAN 128:212667 AN 1998:53500. (drug design, drug discovery, synthesis, SAR, SXR).
1998 - ISHR XX Annual Meeting
Anderson, M.B., Lucchesi, B.R., Kilgore, K.S., et al., INHIBITORS OF SELECTIN-MEDIATED CELL ADHESION. New Frontiers in Cardiovascular Research, International Society for Heart Research (ISHR) XX Annual Meeting, University of Michigan, Ann Arbor, Michigan August 9-12, 1998. (drug design, drug discovery, synthesis, SAR, SXR).
1998 - ISHR XX Annual Meeting
Powers, K.L., Kilgore, K.S., Anderson, M.B., Warren, J.S. STRUCTURAL ANALYSIS OF GLYCOMIMETIC INHIBITORS OF P-SELECTIN-MEDIATED NEUTROPHIL ADHESION. NEW FRONTIERS IN CARDIOVASCULAR RESEARCH, INTERNATIONAL SOCIETY FOR HEART RESEARCH (ISHR) XX ANNUAL MEETING, UNIVERSITY OF MICHIGAN, ANN ARBOR, MICHIGAN August 9-12, 1998. See Journal of Molecular and Cellular Cardiology, 1998, 30(7), A233 poster 2. (drug design, drug discovery, synthesis, SAR, SXR).
1998 - American Journal of Respiratory Cell and Molecular Biology
Kim, Mi-Kyeong; Brandley, Brian K.; Anderson, Mark B.; Bochner, Bruce S. ANTAGONISM OF SELECTIN-DEPENDENT ADHESION OF HUMAN EOSINOPHILS AND NEUTROPHILS BY GLYCOMIMETICS AND OLIGOSACCHARIDE COMPOUNDS. American Journal of Respiratory Cell and Molecular Biology (1998), 19(5), 836-841. CODEN: AJRBEL ISSN:1044-1549. CAN 130:123771 AN 1998:758109. (drug design, drug discovery, synthesis, SAR, SXR).
1998 - Additional Information
Anderson, M.B., Kilgore, K.S., et al. ADDITIONAL NOVEL GLYCOMIMETICS THAT ATTENUATED GLUCAN-INDUCED PULMONARY GRANULOMATOUS VASCULITIS IN THE RAT. UNPUBLISHED.
1997 - Poster & Lecture
Lucchesi, B.R., Kilgore, K.S., Anderson, M.B., et al REDUCTION OF MYOCARDIAL INFARCT SIZE IN VIVO BY GLYCOMIMETICS. American Heart Association (AHA) San Diego, CA 1997. (drug design, drug discovery, synthesis, SAR, SXR, cardiovascular).
1997 - Journal of Surgical Research
Garcia-Criado, F. J.; Palma-Vargas, J. M.; Valdunciel-Garcia, J. J.; Gomez-Alonso, A.; Srivastava, O.; Ezrin, A.; Anderson, M. B.; Toledo-Pereyra, L. H. SULFO-LEWISX DIMINISHES NEUTROPHIL INFILTRATION AND FREE RADICALS WITH MINIMAL EFFECT ON SERUM CYTOKINES AFTER LIVER ISCHEMIA AND REPERFUSION. Journal of Surgical Research (1997), 70(2), 187-194. CODEN: JSGRA2 ISSN:0022-4804. CAN 127:219160 AN 1997:545222. (drug design, drug discovery).
1996 - Tokyo, Japan
Anderson, Mark B and guest. Presentations on cell adhesion and new in vivo pulmonary model related to cell adhesion events. Sankyo Co., Tokyo, Japan.
1996 - Pharmaceutical News
Musser, John H.; Anderson, Mark B.; Fugedi, Peter. GLYCOMIMETICS: AN APPROACH TO DISCOVERING LEADS FOR NOVEL THERAPEUTICS. Pharmaceutical News (1996), 3(5), 11-17. CODEN: PHNEEP ISSN:1071-894X. CAN 126:54385 AN 1997:38145. (drug discovery, review).
1996 - International Medicinal Chemistry Symposium Poster
Anderson, M. B., Kilgore, K, FROM THE PHARAOH'S TOMB TO THE PHARMACY. International Medicinal Chemistry Symposium, September 1996. (drug discovery, drug design)
1996 - Drug News & Perspectives
Musser, John H.; Fugedi, Peter; Anderson, Mark Brian; Rao, Narasinga; Peto, Csaba; Tyrrell, Dave; Holme, Kevin; Tressler, Rob. CARBOHYDRATES AS A SOURCE OF MOLECULAR DIVERSITY FOR DRUG DISCOVERY. Drug News & Perspectives (1996), 9(3), 133-141. CODEN: DNPEED ISSN:0214-0934. CAN 126:98689 AN 1997:30187. (drug design, drug discovery, review).
1996 - ACS Pacific Regional Conference
Anderson, M.B., Lucchesi, B.R., Kilgore, K.S., et al GLYCOMIMETICS AND GRANULOMATOUS VASCULITIS. ACS Pacific Regional Conference, San Francisco, October 1996.
1995 - J Allergy Clinical Immunology
M. K. Kim, B. K. Brandley, M. B. Anderson and B. S. Bochner, ANTAGONISM OF HUMAN NEUTROPHIL (NEU) AND EOSINOPHIL (EOS) ADHESION BY GLYCOMIMETICS AND OLIGOSACCHARIDE COMPOUNDS. The American Academy of Allergy and Immunology, abstract in J. Allergy Clin Immunol., 1995, 95:220. (drug design, drug discovery, synthesis, SAR).
1995 - Current Pharmaceutical Design
Musser, John H.; Anderson, Mark B.; Levy, Daniel E. GLYCOMIMETICS AS SELECTIN INHIBITORS. Current Pharmaceutical Design (1995), 1(2), 221-32. CODEN: CPDEFP ISSN:1381-6128. CAN 124:193057 AN 1996:90745. (drug design, drug discovery, review).
1994 - XVIIth International Carbohydrate Symposium
B. N. Narasinga Rao, M. B. Anderson, J. H. Musser, J. H. Gilbert, M. E. Schaefer, C. Foxall and B. K. Brandley, IDENTIFICATION OF NOVEL SELECTIN INHIBITORS USING SLEX PHARMACOPHORE BASED SEARCH. XVIIth International Carbohydrate Symposium, July 17‑22, 1994, Ottawa, Canada. (drug design, drug discovery).
1994 - Journal of Biological Chemistry
Rao, B. N. Narasinga; Anderson, Mark B.; Musser, John H.; Gilbert, James H.; Schaefer, Mary E.; Foxall, Carrol; Brandley, Brian K. SIALYL LEWIS X MIMICS DERIVED FROM A PHARMACOPHORE SEARCH ARE SELECTIN INHIBITORS WITH ANTI-INFLAMMATORY ACTIVITY. Journal of Biological Chemistry (1994), 269(31), 19663-6. CODEN: JBCHA3 ISSN:0021-9258. CAN 121:148348 AN 1994:548348. (drug design, drug discovery, synthesis, SAR, SXR, inflammation, chemical biology).
1994 - International Business Communications Presentation
Anderson, M. B., GLYCOMIMETIC INHIBITORS OF SELECTINS. TARGETING CELL ADHESION MOLECULES FOR THERAPEUTIC APPLICATION. Sheraton Society Hill Hotel Philadelphia, PA. International Business Communications. December 1‑2, 1994. (drug design, drug discovery, SAR, SXR).
1994 - Immunological Implications of Shock, Trauma and Sepsis
B. K. Brandley, N. Rao, M. B. Anderson, H. Lopez, STRATEGIES FOR THE DESIGN AND USE OF CARBOHYDRATES AND THEIR DERIVATIVES AS ANTI‑INFLAMMATORY THERAPEUTICS. For a Meeting on Immunological Implications of Shock, Trauma and Sepsis in Munich, March 2‑6, 1994. (drug design, drug discovery, shock, trauma, sepsis).
1994 - Burger's Medicinal Chemistry Chapter 22
John H. Musser, Péter Fügedi and Mark Brian Anderson. CHAPTER TWENTY‑TWO: CARBOHYDRATE BASED THERAPEUTICS. Burger's Medicinal Chemistry, Fifth Edition 1994, pages 901‑947. (drug design, drug discovery, review).
1991 - Tetrahedron Letters
Anderson, M. B.; Lamothe, M.; Fuchs, P. L. SYNTHESIS VIA VINYL SULFONES. 41. CYTOCHALASIN, NATURAL PRODUCT SUPPORT STUDIES. 16. INTRAMOLECULAR ACYLATION OF AN ALPHA-SULFONYL ANION GENERATED VIA HALOGEN-METAL EXCHANGE OF AN ALPHA-HALOSULFONE BEARING AN UNSYMMETRICAL ANHYDRIDE. Tetrahedron Letters (1991), 32(35), 4457-60. CODEN: TELEAY ISSN:0040-4039. CAN 115:255658 AN 1991:655658. (synthesis, cytochalasin, natural product).
1991 - Synthetic Communications
Lamothe, M.; Anderson, M. B.; Fuchs, P. L. SYNTHESIS VIA VINYL SULFONES. 40. CYTOCHALASIN, NATURAL PRODUCT SUPPORT STUDIES. 15. SCOPE AND LIMITATIONS IN THE USE OF ALPHA-SILYL AND ALPHA-STANNYL SULFONES AS LATENT ALPHA-SULFONYL ANIONS. Synthetic Communications (1991), 21(15-16), 1675-93. CODEN: SYNCAV ISSN:0039-7911. CAN 115:255715 AN 1991:655715. (synthesis, cytochalasin, natural product).
1990 - Rapid Commun Mass Spectrom
Wood, K. V.; Rothwell, A. P.; Anderson, M. B.; Fuchs, P. L. THE INTRAMOLECULAR MIGRATION OF A TRIMETHYLSILYL GROUP LOCATED ALPHA TO A SULFONE IN SUBSTITUTED CYCLOHEXYL SYSTEMS. Rapid Communications in Mass Spectrometry (1990), 4(1), 1-4. CODEN: RCMSEF ISSN:0951-4198. CAN 114:6582 AN 1991:6582. (synthesis, cytochalasin, natural product).
1990 - Organic Mass Spectrometry
Wood, K. V.; Rothwell, A. P.; Anderson, M. B.; Lamothe, M.; Fuchs, P. L. MASS SPECTRA OF SUBSTITUTED O-TRIMETHYLSILYLPHENYL SULFONES. Organic Mass Spectrometry (1990), 25(8), 423-5. CODEN: ORMSBG ISSN:0030-493X. CAN 114:6593 AN 1991:6593. (synthesis, cytochalasin, natural product).
1990 - Journal of Organic Chemistry
Anderson, M. B.; Fuchs, P. L. SYNTHESIS VIA VINYL SULFONES. 37. CYTOCHALASIN, NATURAL PRODUCT SUPPORT STUDIES. 11. ALPHA-SILYL SULFONES AS LATENT ALPHA-SULFONYL ANIONS. FLUORIDE-PROMOTED INTRAMOLECULAR 1,2-ADDITIONS TO ALDEHYDES AS THE BASIS OF A NEW CYCLOPENTENYLATION STRATEGY. Journal of Organic Chemistry (1990), 55(1), 337-42. CODEN: JOCEAH ISSN:0022-3263. CAN 112:35729 AN 1990:35729. (synthesis, cytochalasin, natural product).
1989 - Purdue Thesis
Anderson, Mark Brian. NEW METHODOLOGIES DIRECTED TOWARDS THE TOTAL SYNTHESIS OF CYTOCHALASIN, NATURAL PRODUCT C AND D. (1989), 498 pp. CAN 114:101467 AN 1991:101467. (synthesis, cytochalasin, natural product).
1988 - Rapid Commun Mass Spectrom
Wood, Karl V.; Rothwell, Arlene P.; Anderson, Mark B.; Fuchs, P. L. EVIDENCE FOR COMPETITIVE INTRAMOLECULAR TRIMETHYLSILYL REARRANGEMENT TO OXYGEN AND SULFUR IN BETA-TRIMETHYLSILYLETHYLTHIOL ESTERS. Rapid Communications in Mass Spectrometry (1988), 2(2), 38-40. CODEN: RCMSEF ISSN:0951-4198. CAN 112:35953 AN 1990:35953. (synthesis, cytochalasin, natural product).
1988 - Journal of Organic Chemistry
Anderson, M. B.; Ranasinghe, M. G.; Palmer, J. T.; Fuchs, P. L. CYTOCHALASIN, NATURAL PRODUCT SUPPORT STUDIES. 10. NUCLEOPHILIC AND ELECTROPHILIC MERCAPTANYLATIONS VIA 2-(TRIMETHYLSILYL)ETHANETHIOL-DERIVED REAGENTS. Journal of Organic Chemistry (1988), 53(13), 3125-7. CODEN: JOCEAH ISSN:0022-3263. CAN 109:170526 AN 1988:570526. (synthesis, cytochalasin, natural product).
1987 - Synthetic Communications
Anderson, M. B.; Fuchs, P. L. CYTOCHALASIN, NATURAL PRODUCT SUPPORT STUDIES. PART 9. AN EFFICIENT METHOD FOR CONVERSION OF CARBOXYLIC ACID DERIVATIVES TO ALLYLSILANES. Synthetic Communications (1987), 17(6), 621-35. CODEN: SYNCAV ISSN:0039-7911. CAN 108:150550 AN 1988:150550. (synthesis, cytochalasin, natural product).
................
References
|
..... |
From Principle To Practice; The Business of Science
|
|